IGF1 and Alzheimer disease: Treatment of APP/PSEN1 mice with recombinant choline acetyltransferase or donepezil improved the AD phenotype, with the former implicated in neuroprotection, synaptic plasticity, neuronal survival and cerebrovascular remodelling, and the latter in altering the immune inflammatory response and insulin/IGF signalling [71].